The present invention relates to a pharmaceutical composition comprising at least one Corynebacterium sp, Staphylococcus pasteuri and, optionally, Staphyloccocus epidermidis for use as a medicament, in particular for use in the prevention or treatment of S. aureus colonization.

Methods are described herein for identifying and providing prebiotic compositions that are optimized for the health needs of individuals.

Methods are described herein for identifying and providing prebiotic compositions that are optimized for the health needs of individuals.

The present disclosure provides compositions comprising encapsulated engineered bacteria. The bacteria may be engineered to act as sensors of biomarkers, such as inflammation, as well as to produce diagnostic or therapeutic agents.

Provided herein are compositions containing fungus, e.g., yeast, useful for treating and/or preventing gastrointestinal inflammation, and/or diseases, disorders, or conditions associated therewith, in a subject in need thereof and methods for using the same.

Flocked substrates are provided as well as methods of use thereof and methods of making.

Flocked substrates are provided as well as methods of use thereof and methods of making.

The invention covers a novel treatment strategy that considerably improves conventional probiotic treatments of inflammatory bowel diseases, irritable bowel syndrome and other gastrointestinal disorders. Both probiotic microorganisms and the carrier of the probiotic microorganisms in form of a fermented cereal gruel are used as treatment effectors. Phospholipids may also be an effecter. The novel treatment strategy is capable of removing the symptoms of inflammatory bowel diseases regardless of a mild, moderate or severe stage of the disease.

The invention covers a novel treatment strategy that considerably improves conventional probiotic treatments of inflammatory bowel diseases, irritable bowel syndrome and other gastrointestinal disorders. Both probiotic microorganisms and the carrier of the probiotic microorganisms in form of a fermented cereal gruel are used as treatment effectors. Phospholipids may also be an effecter. The novel treatment strategy is capable of removing the symptoms of inflammatory bowel diseases regardless of a mild, moderate or severe stage of the disease.

The present invention is a system and method for creating and using algae as a food supplement for cattle and buffalo thereby providing a desirable food supplement for cattle and buffalo wherein the meat and fat produced has increased specific Omega-3 polyunsaturated fatty acids for a product, which imparts a healthier cardiovascular or healthier central nervous system.